Mealey's (August 26, 2021, 1:21 PM EDT) -- NEW YORK — Allegations that the maker of the brand name drug ACTOS mischaracterized the scope of its combination patents to gain an anti-competitive edge will proceed in New York federal court, the Second Circuit U.S. Court of Appeals ruled Aug. 25, affirming a denial of the drug maker’s motion to dismiss....